Background
Phase III RCT. 491 patients with previously untreated DLBCL (all IPI risk groups, unselected). Designed to determine whether DA-EPOCH-R, which showed promise in single-arm studies for PMBCL and high-risk DLBCL, was superior to standard R-CHOP in unselected DLBCL. Key NEGATIVE trial.
Interventions and follow up
Arm A: DA-EPOCH-R (etoposide 50 mg/m²/d CI D1–4 + prednisone 60 mg/m² BID D1–5 + vincristine 0.4 mg/m²/d CI D1–4 + cyclophosphamide 750 mg/m² D5 + doxorubicin 10 mg/m²/d CI D1–4 + rituximab 375 mg/m² D1) × 6 cycles, doses adjusted ±20% per cycle by nadir ANC
Arm B: R-CHOP × 6 cycles
Primary endpoint: Progression-free survival (PFS)
Median follow up: 5 years
Arm B: R-CHOP × 6 cycles
Primary endpoint: Progression-free survival (PFS)
Median follow up: 5 years
Results
PFS (primary): HR 0.93, 95% CI 0.71–1.22, P=.60 — not significant
OS: HR 1.09, 95% CI 0.75–1.59, P=.63 — not significant
ORR: 91% (DA-EPOCH-R) vs 91% (R-CHOP)
OS: HR 1.09, 95% CI 0.75–1.59, P=.63 — not significant
ORR: 91% (DA-EPOCH-R) vs 91% (R-CHOP)
Adverse events
Hematologic (grade ≥3): Neutropenia 71% (DA-EPOCH-R) vs 66% (R-CHOP); anemia 20% vs 12%
Neurologic (grade ≥3): Peripheral neuropathy 9% vs 2%
Mortality/burden: Treatment-related mortality 2% each arm; more hospitalizations and nursing-intensive monitoring with DA-EPOCH-R
Neurologic (grade ≥3): Peripheral neuropathy 9% vs 2%
Mortality/burden: Treatment-related mortality 2% each arm; more hospitalizations and nursing-intensive monitoring with DA-EPOCH-R
Conclusions
DA-EPOCH-R did not improve PFS or OS vs R-CHOP in unselected DLBCL, with greater toxicity in the experimental arm. This definitively confirmed R-CHOP as the standard of care for the general DLBCL population regardless of IPI score.
Key Limitations
Unselected DLBCL population; molecular subgroup analyses (GCB vs ABC, MYC/BCL2 double-hit) were exploratory and underpowered. DA-EPOCH-R continues to be used for PMBCL and MYC-rearranged DLBCL on non-randomized evidence, suggesting the negative result may not apply to all subtypes. The dose-adjustment protocol requires intensive monitoring. CNS prophylaxis was not mandated.
Clinical Context
CALGB 50303 is practice-confirming: R-CHOP×6 remains the global first-line standard for DLBCL (ESMO). DA-EPOCH-R is reserved for PMBCL, HIV-associated DLBCL, and select double-hit DLBCL. This trial prevented widespread adoption of DA-EPOCH-R as a general DLBCL backbone. Novel additions to R-CHOP (polatuzumab in POLARIX) represent the current direction for first-line intensification.
References